Letter to the Editor Open Access

Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug

Mohamed Nabil Ibrahim1 and Abdo Abdellah Elfiky2
  • 1 Jouf University, Saudi Arabia
  • 2 Cairo University, Egypt


The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.

American Journal of Biochemistry and Biotechnology
Volume 17 No. 2, 2021, 205-207

DOI: https://doi.org/10.3844/ajbbsp.2021.205.207

Submitted On: 2 March 2021 Published On: 10 May 2021

How to Cite: Ibrahim, M. N. & Elfiky, A. A. (2021). Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug. American Journal of Biochemistry and Biotechnology, 17(2), 205-207. https://doi.org/10.3844/ajbbsp.2021.205.207

  • 0 Citations



  • Sofosbuvir-COVID-19-RNA Polymerase-Therapy